Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Ricketts

Gastroenterology Chesapeake, VA Medical Doctor

NPI 1326222928 CMS profile 196522

113 Gainsborough Sq Ste 202, Chesapeake, VA 23320

Open in the dashboard

General payments

$9,391

503 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Ricketts of Chesapeake, VA is reported in the CMS Open Payments database as having received $9,391 across 503 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,584 73
2024 General $1,306 62
2023 General $1,124 63
2022 General $1,533 89
2021 General $1,514 81
2020 General $994 58
2019 General $1,336 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Ricketts
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Paul Ricketts were reported at $1,584. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Paul Ricketts Gastroenterology median Middle half National median
2019 $1,336 $417 $126–$1,100 $163
2020 $994 $224 $74–$624 $114
2021 $1,514 $352 $106–$1,054 $132
2022 $1,533 $448 $129–$1,270 $149
2023 $1,124 $533 $150–$1,390 $160
2024 $1,306 $605 $160–$1,606 $164
2025 $1,584 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,276 170 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $953 58 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $912 58 payments
  4. Janssen Biotech, Inc. $841 47 payments
  5. Celgene Corporation $444 33 payments
  6. Daiichi Sankyo Inc. $400 20 payments
  7. Regeneron Healthcare Solutions, Inc. $316 14 payments
  8. Ardelyx, Inc. $191 9 payments
  9. Nestle HealthCare Nutrition Inc. $148 9 payments
  10. Pfizer Inc. $136 8 payments
  11. Other $1,772 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,213 499 payments
  2. Education $178 4 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $1,316 70 payments
  2. RINVOQ $1,144 59 payments
  3. STELARA $941 47 payments
  4. XIFAXAN $701 40 payments
  5. ENTYVIO $689 39 payments
  6. SKYRIZI Immunology $582 27 payments
  7. ZEPOSIA $569 34 payments
  8. SKYRIZI Immunology $564 23 payments
  9. CREON $536 32 payments
  10. SIMPONI $436 25 payments
  11. Other $4,338 244 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,000

Median for Gastroenterology: 569

Drug cost

$245,277

Median for Gastroenterology: $104,976

Branded share of claims

29%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 13 $114,353
Linzess Linaclotide Brand 33 $42,242
Xifaxan Rifaximin Brand 12 $37,355
Trulance Plecanatide Brand 13 $10,989
Mesalamine Generic 14 $8,273
Movantik Naloxegol Oxalate Brand 16 $6,418
Dexlansoprazole Dr Dexlansoprazole Brand 25 $6,371
Lubiprostone Generic 20 $4,423
Colestipol Hcl Generic 42 $2,676
Pantoprazole Sodium Generic 165 $2,584

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$161,939

Medicare's payments for the services billed

Medicare patients

629

Average age 72

Services billed

1,113

371 women, 258 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 34%
Depression 28%
Ischemic heart disease 27%
Chronic kidney disease 24%
COPD 20%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $205
$205 13 —
SKYRIZI
  • AbbVie, Inc. $150
$150 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $126
$126 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $103
$103 — —
HUMIRA
  • AbbVie, Inc. $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

503 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record